SummaryAltered O-glycosylation of cancer cells is frequently associated with metastasis and poor prognosis. During metastasis, cells must also lose their epithelial characteristics and become mesenchymal and motile, termed epithelial-mesenchymal transition (EMT). While it is established that transforming growth factor beta-1 (TGF-β1) can induce EMT, the effect of cytokine-induced EMT on O-glycosylation of breast cancer cells has not previously been explored. MCF-7 and T47-D breast cancer cells were treated with TGF-β1 over a time course of up to 7 days. Morphological changes were assessed using confocal microscopy and quantified; levels of EMT marker expression were assessed using immunofluorescence with confocal microscopy and western blot. The effect of TGF-β1 on synthesis of unelaborated Tn antigen was explored using Helix pomatia agglutinin (HPA) labelling. TGF-β1 treatment induced morphological changes, resulting in an elongated, mesenchymal-like phenotype, and a reduction of epithelial marker E-cadherin but did not detectably induce mesenchymal markers N-cadherin or vimentin. It also resulted in a significant reduction in unelaborated Tn antigen, detected by HPA labelling. These observations are consistent with TGF-β1 inducing an 'early' or partial EMT state over this timeframe, and a concomitant change in O-glycosylation, consistent with the synthesis of more elaborated O-glycan structures; such glycoplasticity may function in metastasis.â(J Histochem Cytochem XX:XXX-XXX, XXXX).
Transforming Growth Factor-β Drives Epithelial Mesenchymal Transition and Reduces Synthesis of Unelaborated O-GalNAc Glycans in Breast Cancer Cells.
阅读:4
作者:Cull Joanna, Pink Ryan C, Samuel Priya, Brooks Susan A
| 期刊: | Journal of Histochemistry & Cytochemistry | 影响因子: | 1.500 |
| 时间: | 2026 | 起止号: | 2026 Mar-Apr;74(2):193-214 |
| doi: | 10.1369/00221554261416994 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
